When we were younger, we probably didn’t give much thought to how soft and full our hair was. As we get older, however, we could notice that our hair is less full and more brittle. Because hair grows at a rate of less than half an inch per month, the hair on your head has been subjected to the harmful effects of the sun and other environmental factors for many years. It is also influenced by naturally declining hormone levels, which are linked to changes in hair growth, structure, and greying. These factors all play a role. Androgenetic alopecia, more commonly referred to as male baldness, is the form of hair loss that occurs more frequently in both men and women.
WHAT EXACTLY IS THE PTD-DBM?
The designation PTD-DBM refers to the combination of the terms “Protein transmission domain” (PTD) and “Dvl-binding motif” (DBM)
It is a therapy for the regeneration of hair follicles, to put it more simply. To be more exact, this is composed of peptides eTo put it another way, it is a treatment that promotes the growth of new hair follicles in the scalp. To be more specific, this treatment is an external therapy that is based on peptides and is administered to the scalp. This medicine inhibits the function of the hormone that causes follicles to shrink. hormones in the body produced by the body, so successfully saving the follicle at the stem cell level. PTD-DBM treatment not only stops the progression of balding but also stimulates the creation of new follicle.
Many experts are of the opinion that the WNT signalling pathways found inside a cell are the ones that are responsible for the growth of hair follicles and the regeneration of hair in people. These pathways are often composed of proteins, and they are responsible for transmitting crucial signals regarding cell activity and growth to numerous cells located all throughout our body.
The Exploration and Detection of PTD-DBM
Androgenetic alopecia is a disorder that is characterised by excessive loss of hair in men. A team of researchers at South Korea University, found a protein that is responsible for this hair loss. The action of this protein is controlled by a newly created chemical that was generated by the researcher to enhance hair regeneration. This protein is responsible for controlling the development of hair.
The protein in question is known as CXXC-type zinc finger protein 5 (CXXC5), and it plays the role of a negative regulator on the Wnt/-catenin pathway. This pathway is associated with both wound healing and the regeneration of hair. When CXXC5 connects with a protein known as the Dishevelled protein, it inhibits the development of hair follicles and stops hair from growing back. Those of us who wish to maintain our hair will not benefit from this in any way. Because of this, a novel biological substance known as PTD-DBM was developed, and it is capable of disrupting the binding process.
It has been demonstrated in human hair follicle dermal papilla cells that PTD-DBM has a beneficial effect on the regeneration of hair. As a result of the positive results obtained with PTD-DBM, further investigation was conducted, and it was determined that the most effective treatment for hair regeneration would involve a three-pronged strategy.
Microneedling is another name for wound-induced hair neogenesis. Rolling needles that are extremely fine across the surface of the skin in order to pierce it is one method of therapy for androgenetic alopecia. Dermarollers are the name given to these tools. They are applied by hand and rolled over the treatment region to produce a “wound” and assist in the development of new hair follicles. Because it causes only minimal damage to the surface of the skin, microneedling is frequently used as a treatment for the skin. It has also been shown to stimulate the creation of collagen and other healing elements.
PTD-DBM targeting of the CXXC5 protein.
Valproic acid. Typically employed as a treatment for epileptic seizures, bipolar disorder, schizophrenia, and migraines. In this particular instance, a topical application of it was employed to activate the Wnt/-catenin pathway.
As a result, the therapy utilises a three-pronged approach. The “wounds” that are caused by microneedling cause the production of follicles; the valproic acid activates the cell pathway that is associated to the development of follicles; and the PTD-DBM inhibits CXXC5 from interfering with the process of follicular development. When the researchers combined these three methods, they found that the hair grew back in an even more rapid manner.
PTD-DBM and valproic acid are both available in the form of topical sprays that are administered to the scalp on a regular basis. Dermarollers, which are used for microneedling, are often utilised once or twice a week.
The use of a competitive peptide to target CXXC5 has been shown to stimulate hair regrowth as well as wound-induced hair neogenesis. Volume 137, Issue 11 of the Journal of Investigative Dermatology, November 2017, Pages 2260-2269
Healing of cutaneous wounds is inhibited by the Dishevelled-binding protein CXXC5, which also plays a role in inflammation. J Exp Med. 2015 Jun 29; 212(7): 1061–1080. doi: 10.1084/jem.20141601
Valproic acid stimulates the production of alkaline phosphatase activity in human dermal papilla cells and promotes hair regrowth in a mouse model of the condition. PLoS One. 2012;7(4):e34152. doi: 10.1371/journal.pone.0034152.
The researchers that carried out the study. In an in vitro cell model of human hair development, valproic acid was found to be beneficial. J Dermatol Sci. 2013 Oct;72(1):16-24. doi: 10.1016/j.jdermsci.2013.05.007.